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Chapter 10 
LIVER 
TRANSPLANT ATION 
Carlos O. Esquivel, M.D., Ph.D. 
Thomas E. Starzl, M.D., Ph.D. 
The consequences of end-stage liver disease in children 
are devastating. Children with such diseases suffer from the 
problems associated with portal hvpertension and the effects 
of malabsorption. particularlv those children with chronic 
cholestatic liver disease. A typical example is the growth 
failure and rickets in children with biliary atresia. even those 
with successful portoenterostomies.o 
Liver disease in children may be classified in three broad 
categories for didactic purposes: (1) chronic cholestatic liver 
disease. which accounts for approximately 75 percent of the 
diseases treated with transplantation; (2) inborn errors of 
metabolism. constituting approximately 20 percent of the 
indications; and (3) post-hepatic cirrhosis. Primary liver ma-
lignancy is an unusual indication for liver transplantation in 
children. 10 
Liver transplantation is becoming a routine surgical 
intervention in many centers in North America and Europe. 
in spite of the fact that it was considered to be an experi-
mental operation just a few years ago.3J The experience with 
pediatric liver transplantation at the University of Pittsburgh 
during the cyclosporine era is discussed here in more detail. 
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SURGICAL ASPECTS 
The Donor 
A significant problem in pediatric transplantation is the 
scarcitv of small donors. In the l"nited States, organs are 
retrieved from ()nlv approximatel" 1 j to 20 percent of 
potential clollors. owing to resistance from the medical 
profession and from people in general. ;\lthough organ 
donation in the L' nited States is \·oluntarv. a "required 
request"' law-which compels hospitals to approach the fam-
ilies of potential donors-has recenth been passed in man" 
states in an attempt to increase the donor supply. 
The donor should be selected expeditiouslv and care-
fully. Information must be obtained about the cause of death 
and about prior infections, including exposure to hepatitis 
or HIV (human immunodeficiency \irus) infection, and am 
history of malignancy. J. 28. 32 
The following laboratorv tests ought to be performed: 
hepatic transaminase levels (alanine aminotransaminase. as-
partate arninotransaminase), total and direct bilirubin. and 
prothrombin time. Serology tests for HIV, hepatitis B. and 
cytomegalovirus (CMV) should also be performed. The latter 
is verv important in children, because many have never been 
exposed to eMV and the risk of transmission is very high. 
The donor should receive whatever is necessary, such as 
blood transfusions, oxygen, and vasopressors, in order to 
maintain hemodynamic stability. Hepatic congestion must be 
prevented by the judicious administration of fluids and 
careful monitoring of central venous pressure. 
It is difficult to predict graft function. In a previous 
investigation the oxygenation of the donor had an important 
correlation with graft function, but other factors studied, 
such as bilirubin values, transaminase values, and adminis-
tration of vasoactive substances, had little or no bearing on 
graft outcome. i 
To minimize graft dysfunction the technique of harvest-
ing has been modified. 39. 42 As performed currently in Pitts-
burgh, the harvesting is based on rapid flushing of the organs 
followed by removal en bloc. 42 Undoubtedlv, the most im-
portant principle is rapid cooling of the orga~sK The primarv 
graft dysfunction in some patients may represent a form of 
accelerated rejection, as some data indicate.2 
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The progress in the development of new solutions for 
preservation has been slow since the introduction into clinical 
practice of Collins' solution. Nevertheless, Belzer's group 
from the U niversitv of Wisconsin recentlv reported their 
successful experience with a new solution for the preservation 
of the liver for up to 24 hours.cl This has been conhrmed 
experimentally at our institution. 
The Recipient 
Liver transplantation is offered when a child develops 
manifestations of portal hypertension such as variceal bleed-
ing, ascites, or hvpersplenism. It should also be considered 
when the child's growth and development stop as the result 
of end-stage li\"er disease. For obvious reasons, li\"er replace-
ment should not be deferred until the patient is moribund, 
nor should the patient be subjected to an unnecessary op-
eration that may jeopardize a future transplant, such as re-
vision of portoenterostomv or mesocaval or portacaval 
shunt.ll. ~-I 33 The distal splenorenal shunt is safer because 
the dissection is not in the hepatic hilum: however. it mav 
still predispose to shrinkage or even thrombosis of the portal 
\'ein, limiting the opportunity for a liver transplant.' i 
Venous Bypass 
The techniques of hepatic transplantation have been 
reported in detail e1sewhere.39 There are, however, some 
subtle differences between pediatric and adult liver trans-
plantation. One is the use of venous bypass during the 
anhepatic phase. 3G Unlike adults, many children tolerate the 
anhepatic stage very well. This does not mean that the venous 
bypass is superfluous in children. In fact, the renal and 
intestinal insult, as well as the fibrinolysis triggered bv pro-
longed clamping of the portal vein, is significantly minimized 
when the venous bypass is used.36 
Venous bypass may be used safely in children who weigh 
more than 15 kg; the size of the veins is the limiting factor 
in smaller children. In our experience the size of the venous 
cannulae should be at least No. 12 French for the axillary 
and femoral veins and No. 16 French for the portal vein. If 
'" 
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the axillarv vein is too small to allow passage of the cannula, 
the alternative is to use the junction of the external jugular 
vein and the subclavian vein, which is exposed through a 
small incision placed between the insertion of the heads of 
the sternocleidomastoid muscle. Flows greater than 1000/ml 
per minute are ideal. although transplants have been per-
formed saielv \Iith lesser Hows.n Obviously. low How mav 
predispose to thrombosis and fatal embolism. 
Arterial Reconstruction 
Arterial reconstruction in children calls for a perfect 
vascular technique. Any technical error inevitablv leads to 
thrombosis, one of the most feared complications in trans-
plantation. ll ; Technical complications may not be the onlv 
factors implicated in hepatic artery thrombosis. Other poten-
tial contributing conditions are rejection causing an outflow 
resistance, as has been demonstrated angiographicallv; vas-
cular anomalies; vascular grafts in difficult reconstructions: 
and overmanipulation of the coagulation system with clot-
promoting substancesK~9K 38. H. -/8. 50 The best results are ob-
tained with an end-to-end anastomosis between the donor 
celiac axis and the recipient'S common hepatic artery or celiac 
axis. 30 
It is also important to prevent a state of hypercoagulation 
during the immediate postoperative period. Fresh-frozen 
plasma and platelets are not administered during surgery 
unless the patient has a life-threatening hemorrhage. Fur-
thermore, at the end of the procedure the patient is given 
Dextran 40 for 5 days, aspirin, and dipyridamole (Persan-
tine). In certain cases full heparinization may be necessarv. 
Portal Vein Reconstruction 
Troubling reconstructions of the portal vein usuallv 
occur in patients with extrahepatic biliary atresia who have 
had numerous operations in the hepatic hilum, such as 
multiple revisions of portoemerostomies or portosystemic 
shunts or both. The reconstruction of the portal vein may 
also be difficult in retransplantation, particularly in the pres-
ence of peritonitis. 
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A significant number of patients with biliary atresia do 
have hypoplastic portal veins. and often patients already have 
portal vein thrombosis bv the time thev are referred to us 
for transplantation. 
Hvpoplastic or thrombosed portal veins are not suitable 
vessels for reconstruction: thus. the anastomosis in such cases 
is performed at the junction of the superior mesenteric vein 
(SY!V) and splenic vein (SV) after removing the entire 
diseased portal vein. Interposition venous grafts using donor 
iliac veins are necessary when the donor liver is small and 
the length of the portal vein does not reach the junction of 
SMV and SV. 1j In these cases the venous graft should be 
anastomosed to the junction of the SMV and SV before the 
hepatectomy is performed. especially when venous bypass is 
not used. I f the sequence of steps is changed and the 
hepatectomv is performed first. the anastomosis of the ve-
nous graft with the junction of SMV and SV may be difficult 
and hazardous because of inadequate exposure due to tissue 
edema from prolonged clamping of the vena cava and portal 
vein. 
BILIARY TRACT RECONSTRUCTION 
The most common tvpe of reconstruction used in chil-
dren is the choledochojejunostomv into a Roux-en-Y limb 
because of the absence (due to biliary atresia) or small size 
of the common bile duct.-Io.42 A primary end-to-end recon-
struction with a small common bile duct is cumbersome 
because of the lack of appropriate-sized T tubes. The smallest 
commercially available T tube is No. 5 French. In older 
children with normal recipient common bile duct the recon-
struction may be done end-to-end using a T tube. which is 
removed 2 to 3 months following transplantation. The anas-
tomosis is performed with interrupted absorbable 6-0 su-
tures (e.g., Maxon or Vicrvl). The vertical limb of the T tube 
is carried through the native bile duct as far as possible from 
the anastomosis and then brought out of the abdomen 
through a separate stab wound. The T tube is then connected 
to a bag. Inspection of the bile may help in the diagnosis of 
graft dysfunction. including rejection. 
The choledochojejunostomy is made end-to-side with 
interrupted absorbable 6-0 stitches. A stent 3 to 5 em long 
.' , 
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is used for this anastomosis and is secured in place with a 
single stitch of 6-0 chromic suture. The diameter of the 
stent should be the largest that slides with ease into the 
common bile duct. Forcing larger stents into the common 
bile duct may create pressure necrosis, which is followed by 
a bile leak and peritonitis. 
The stent is made bv cutting the distal 3- to 5-cm segment 
of a Salem nasogastric tube. A few holes are then made on 
the side to facilitate bile drainage. and the radiopacity of the 
Salem nasogastric tube facilitates its location with a plain film 
of the abdomen. The stents usually are dislodged and elim-
inated in the stool 2 to 4 weeks after the operation. 
IMMUNOSUPPRESSION 
The regimen of immunosuppression used at the Cni-
versitv of Pittsburgh consists of cyclosporine and small doses 
of corticosteroids. lU. 41 Triple-drug therapy, which includes 
the addition of azathioprine, or quadruple-drug therapy 
(azathioprine, antilymphocytic globulin. cyclosporine. and 
corticosteroid) is used frequently in other institutionsK~1K H 
Cyclosporine 
The introduction of cyclosporine (Sandimmune) to clin-
ical practice dramatically changed the outcome of liver trans-
plantation, and the survival rate has more than doubled. The 
initial dose of cyclosporine is 6 mg/kg per day (IV) divided 
in three doses, but children often require much higher doses 
in order to reach the trough level of at least 1000 ng/ml that 
is considered in the therapeutic range. Likewise, the initial 
dose of oral cyclosporine is 20 mg/kg per day divided in two 
doses, but more often higher doses are required to achieve 
adequate trough levels.' The reason is that children metab-
olize cyclosporine faster than adults and frequently have 
transient malabsorption following transplantation.5 More-
over, some children take phenobarbital or dilantin for seizure 
control, and such drugs are known to lower the cyclosporine 
level. Children tolerate high doses of cyclosporine well since 
they usually have excellent renal function. 
Intravenous cyclosporine is discontinued when adequate 
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levels can be maintained with oral administration. This is a 
gradual process that takes I to 6 weeks. 
Corticosteroids 
Postoperativelv. corticosteroids are administered intra-
venouslv until the paralvtic ileus is resolved. The initial dose 
of methdprednisolone sodium succinate (Solu-Medrol) is 100 
mg divided into tour doses. Subsequentlv. the dose is tapered 
bv 20 mg daily. to end with a maintenance dose between 5 
and 20 mg per dav. depending on the weight of the patient 
(this is called a recycle of steroids in our institution). The 
methylprednisolone is changed to prednisone when the pa-
tient tolerates oral feedings. '" The eventual maintenance dose 
is approximately 0.2 mg/kg per dav to allow normal linear 
growth in children. 17 
Corticosteroids also are used in the treatment of acute 
rejection; the dosage depends on the severity of the rejection 
and the weight of the patient. ~fild rejection may be brought 
under control bv a single intravenous pulse of hydrocortisone 
sodium succinate (Solu-Cortd). 0.5 mg. A full recycle of 
corticosteroids should be given in the presence of severe 
rejection. 
Monoclonal Antibodies 
Recentlv. the monoclonal antibody OKT3 (Orthoclone) 
has been added to the immunosuppressive armamentarium. lo 
OKT3 has been found to be effective in reversing cell-
mediated rejection in liver transplantation in almost 90 per-
cent of patients. It has improved early survival and has 
decreased the incidence of retransplantation.9. 28 This mono-
clonal antibody also has been used more than once in a given 
patient; this is possible provided that murine antibodies are 
not detected in the serum. 
The recommended dose in children is 2.5 ml intrave-
nously daily for 2 weeks. Although the side effects usually 
are ~ild it is advisable to premedicate patients with 0.5 g 
hydrocortisone (IV) for the first two doses, and acetami-
nophen and diphenhydramine hydrochloride (Benadryl) 
for the entire length of the treatment. OKT3 is the 
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treatment of choice for steroid-resistant acute reJec-
tionK~D lb. ~i 
INDICATIONS AND RESULTS 
I n the c\ciosporine era. 334 pediatric patients underwent 
liver transplantation between March 1980 and Julv 1987 at 
the l' niversit\ of Pittsburgh Health Centers. The most com-
mon diagnostic indications were biliarY atresia (both extra-
;ltld intrahepatic !'pes). inborn metabolic errors such as U,-
antitrypsin dehciencv. tYrosinemia. Wilson's disease. and 
posthepatic cirrhosis. Other less frequent indications are 
listed in Table 10-1. 
Survival According to Diagnosis 
The overall actuarial survival rates for the entire group 
were 72 and 66 percent at 1 and 5 years. respectivelv. The 
survival of 168 children with extrahepatic biliarv atresia was 
70 percent at 1 year and 65 percent at 5 years. In contrast. 
survival in the group with intrahepatic biliarv atresia (Ala-
gille's syndrome) was 54 and 44 percent at 1 and 5 Years. 
respectivelv. Three children with Alagille's syndrome died 
during the immediate postoperative period of complications 
of pulmonary hypertension with cardiovascular collapse. 
Survival for patients with inborn errors of metabolism is 
Table 10-1. DIAGl\OSTIC INDICATIONS FOR 
LIVER TRANSPLANTATION BEFORE AGE 18 YEARS 
Indication No. Percent 
Biliary atresia 178 ,-,3.3 
Inborn errors of metabolism 63 18.9 
Postnecrotic cirrhosis 40 12.0 
Familial cholestasis 15 4.5 
Fulminant hepatitis 13 3.9 
Congenital fibrosis 7 2.1 
Secondary biliary cirrhosis 7 2.1 
Primary hepatic tumors 4 1.2 
Budd-Chiari syndrome 2 0.6 
:\" eonatal hep~titis 2 0.6 
Trauma 0.3 
Pseudoinftammatory tumor 0.3 
Sclerosing cholangitis U.3 
~ . 
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somewhat better than for those with biliarv atresia. At 1 and 
5 years. the actuarial survival rates were 80 and is percent. 
respectively. The most common diagnostic indication in this 
group was a I-antitrvpsin deficiency. and the long-term sur-
vival rate exceeds 80 percent. 
The prognosis in patients with post necrotic cirrhosis is 
\'erv good: actuarial survival is 81 percent at I vear and ii 
percent at :J \ears (Fig-. 10-1). 
Survival According to Age 
The age of the patient at the time of transplantation has 
little bearing on the long-term outcome. perhaps with the 
exception of children vounger than 1 vear of age. In the 
latter group. the surviyal rate is 66 percent at 6 months and 
65 percent at 1 year; however. it is 3i percent at 5 years. 
with only one patient at risk. The actuarial survival rate after 
3 years is difficult to assess: because there are so few patients 
at risk (twO). a single death would have significant impact on 
the survival curye. On the Olher hand. the survival at 1 vear 
is no different from that of older patients (Fig. 10-2). 
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Figure 10-1. Effect of underlving liver disease on actuarial survival rate 
after hepatic transplantation. The difference is not statistically signiticant. 
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Figure 10-2. Impact of age at the time of hepatic transplantation on 
actuarial suryi,al rate. L·p to age I year there is no signIficant difference: 
thereafter. the suryiyal rate is decreased among infants. 
Retransplantation 
Almost one out of four children eventuallv requires 
retransplantation. The indications are rejection in 43.3 per-
cent. technical complications in 43.3 percent. and primarv 
graft nonfunction in 13.4 percent. 10 Arterial thrombosis 
accounts for most of the technical complications requiring 
retransplantation. The survival depends on the indication or 
on the number of transplants. Retransplantation for primary 
graft non function is associated with the poorest survival rate, 
approximatelv 10 percent. For the other two indications the 
survival rate approaches 50 percent when the indication was 
technical complications and 79 percent when the reason for 
retransplantation was rejection. Likewise, survival in patients 
with primary transplants is 75 percent; with secondary and 
tertiary transplants it is approximatelv 50 percent and 35 
percent. respectively. 
Quality of Life 
Qualitv of life for transplant reCIpients has been the 
subject of several reports. 14. 20. 49 The social and vocational 
-... -' 
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reintegration of liver transplant recIpients is good. It is 
remarkable to observe the changes soon after transplantation 
as the children become interested in their environment and 
their appetite graduallv improves. Debilitated children who 
did not have enough strength before transplantation begin 
to walk soon afterward. Certainly. some children with major 
sequelae from the ravages of the underlying disease require 
rehabilitatioll. 
l'rbach and coworkers reported the impact of liver 
transplantation 011 the linear growth of children. 17 Roughlv 
7t percent of the patients had good linear growth following 
transplantation. and several crossed percentiles in an upward 
direction. The common denominator in the majoritv of 
children whose growth was poor was high doses of steroids 
for repeated bouts of rejection. 
COMMENTS 
Chronic cholestatic liver disease accounts for almost two 
thirds of the indications for liver transplantation in children. 
The hepatic lesion in this group of diseases is characterized 
bv a bile duct injurv with impairment of bile excretion. often 
leading to cirrhosis. Biliary atresia is the most common 
disease among this group, representing 53 percent of all 
indications for pediatric liver transplantation. Complications 
after liver transplantation for biliary atresia are significant 
owing to previous operations in the hepatic hilum (e.g., 
extrahepatic biliarv atresia) or to associated medical problems 
such as pulmonary hypertension in the Alagille's syndrome 
patients. 7• 13 Previous abdominal operations definitely increase 
the postoperative morbidity rate, particularly in patients with 
portoenterostomies. These patients often suffer frequent 
bouts of cholangitis, which lead to further deterioration of 
the clinical condition. Some are left with stomas in an attempt 
to minimize the problems of cholangitis. but such stomas also 
are associated with significant complications, such as bleeding 
and contamination during the transplant operation. More 
importantly, they may not prevent the episodes of cholangitis. 
While stable patients are waiting for liver transplantation 
stomas should be taken down. 
The inborn metabolic or genetic disorders fall into three 
;.. 
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different categones: (1) those based in the liver that are 
associated with a hepatocvte injury (e.g., al-antitrvpsin defi-
ciency, tyrosinemia. and others),I.I·:l1. ~:f (2) extrahepatic-based 
disorders with associated liver injury. such as cystic fibrosis;" 
and (3) those based in the liver that are not associated with 
hepatic injurY. such as the defects of the urea cycle. i\[ost of 
t he metabolic disorders treated \\'ith hepatic transplantation 
belong- to the first group. I The long-term outcome is excel-
lent. and the hepatic replacement cures the underlying met-
;tbolic defect. :,. \. en fe\\" patients \Iith cystic fibrosis and 
mher rare disorders and lIith assoCIated end-stag-e liler 
disease ha\'e undergone transplantation successfullv. One of 
these patients with the syndrome of :\eville did develop a 
recurrence of the underlving- disease. " 
:\.S results imprOle with the introduction of new immu-
nosuppressive and preservation agents. liver transplantation 
will be offered to patients with metabolic disorders based in 
the liver before the onset of systemic complications. even in 
the absence of hepatic disease. Several diseases fall into this 
category. such as defects of the urea cvcle. some of the 
lipidoses. and others. 
Postnecrotic and posthepatic cirrhosis are less common 
indications for pediatric liver transplantation. :'\[ost are sec-
ondarv to non-A or non-B hepatitis. and the overall results 
;tre verI' good. Hepatitis B as an indication is extremelv rare 
in children. ~u 
Liver transplantation in infants is associated with signif-
icant morbidityKl~ The main complications are primary graft 
nonfunction, vascular thrombosis, and intestinal perforation. 
Many of these infants are in very poor medical condition at 
the time of transplantation, and the urgency may not allow 
them to wait for optimal grafts since the shortage of small 
organs is a serious problem. To alleviate this problem, many 
centers are reducing the size of the liver by doing partial 
resections before implantation. 1M 
Most deaths after pediatric transplantation occur within 
the first 6 months.22 If the patients survive this critical period, 
the long-term outlook is excellent. The majority of patients 
are restored to a normal life style, which is more than enough 
incentive to continue with the demanding task of caring for 
children with end-stage liver disease before and during the 
critical posttransplantation period. 
S"l 
reI 
19~ 
rna 
livt 
dis 
ate 
tht 
of 
su\ 
lift 
Re 
I. 
3. 
:J, 
Ii. 
i. 
H. 
9. 
10. 
11. 
12. 
13. 
14. 
~I; 
:.;' 
LIVER TRANSPLA:\TATIO:\ 0 141 
SUMMARY 
The survival rate after liver transplantation increased 
remarkably following the introduction of cyclosporine in 
1980 and \lith improvements in surgical techniques and 
lqlana~ement during the perioperative period. ~[ost pediatric 
liver transplant candidates suffer from chronic cholestatic 
disease or from liver-based metabolic disorders with associ-
;lted cirrhosis. III the latter group. lin'r transplantation cures 
(he uIHJerh'ing metabolic detect bv conferring the phenotvpe 
()f the donor. The rehabilitation of pediatric patients after 
successful li\er transplantation is excellent, and most enjoy 
life stvles similar to t hose of normal children. 
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